DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. Yet, the recent COVID-19 pandemic highlighted the obstacles that are inherent today in the development of vaccines. Stabilizers play a crucial role in maintaining the vaccine's potency and integrity throughout its shelf life.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

FDA Law Blog: Biosimilars

APRIL 7, 2025

Zenrelia comes with serious warnings, including a boxed warning against the use of Zenrelia during vaccination. CVM also objected to the truncation of other information about the timing of vaccines in these promotional materials. Further, information presented on the adverse reaction data was inconsistent with the PI.

52

52

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Vaccine 81

Vaccine FDA Hospitals International 81

SCIENMAG: Medicine & Health

JUNE 8, 2023

ECU Centre for Precision Health Clinical Professor Adnan Khattak presented the trial’s latest results at the 2023 American Society of Oncology (ASCO) congress in Chicago this week, the biggest […]

Treatment 90

Treatment Vaccine Trials Research 90

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We Poster presentation number 1137. Poster presentation number 1046. Poster presentation number 3. In the U.S.,

Vaccine 52

Vaccine Research Virus Disease 52

Conversations in Drug Development Trends

MAY 30, 2024

Other researchers are investigating approaches that use AAV-mediated trophic support and antibody-based therapies, such as vaccines and small molecule drugs, to modify various protein expressions. The post Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies appeared first on Worldwide Clinical Trials.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

MAY 14, 2021

Product Name: Gutamin7 – Presentation. Click here to get Gutamin7 – Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. © 2021 Copyright: Gutamin7.com.

Compliance 52

Compliance Production Regulations Doctors 52

The Pharma Data

MAY 14, 2021

Product Name: cellulite removal video presentation. Click here to get cellulite removal video presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Production 52

Production Vaccine 52

The Pharma Data

MAY 14, 2021

Product Name: GlucoFlow – Presentation. Click here to get GlucoFlow – Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Try GlucoFlow for yourself, completely risk free.

Packaging 52

Packaging Production Compliance Doctors 52

The Pharma Data

MAY 14, 2021

Product Name: Weight Dissolver – Video Presentation. Click here to get Weight Dissolver – Video Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. © 2019 Copyright: WeightDissolver.com.

Production 52

Production Compliance Testimonials Regulations 52

The Pharma Data

MAY 15, 2021

Product Name: Dentitox Pro – Text Presentation. Click here to get Dentitox Pro – Text Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Read more here.

Production 52

Production Packaging Nurses FDA Approval 52

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. Findings from a leading-edge study called TRACERx have demonstrated how mutations that occur very early in the process of cancer genesis remain present in all cells of a growing tumour.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

MAY 14, 2021

Product Name: Free High Blood Pressure Presentation. Click here to get Free High Blood Pressure Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Testimonials 52

Testimonials Medical Schools Nurses Production 52

The Pharma Data

MAY 14, 2021

Product Name: Sweat Miracle™ – FREE Video Presentation. Click here to get Sweat Miracle™ – FREE Video Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Doctors 52

Doctors Production Pharmacy Vaccine 52

Drug Target Review

OCTOBER 2, 2023

Immunopeptidomics is a rapidly expanding field at the intersection of immunology and proteomics that focuses on the identification and characterization of peptides presented by major histocompatibility complex (MHC) molecules, also known as the human leukocyte antigen (HLA), on cell surfaces. Research Square. 2023 [cited 2023 Sep 21].

Immune Response 105

Immune Response Vaccine Disease Research 105

The Pharma Data

OCTOBER 6, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

The Pharma Data

OCTOBER 9, 2021

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS.

Immune Response 52

Immune Response Vaccine Treatment Therapies 52

keypoint

JANUARY 23, 2023

On March 24, 2023, Keystone Symposia will hosted a live ePanel event featuring the recipients of the Michelson Prizes: Next Generation Grants , an international prize that supports early-career researchers who are applying disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research.

Vaccine 52

Vaccine International Research 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

MAY 15, 2023

The vaccine candidate demonstrated non-inferiority in primary endpoints for five Neisseria meningitidis serogroups (A, B, C, W, and Y) compared to two doses of Bexsero (meningococcal group B vaccine) and one dose of Menveo (meningococcal group A, C, W-135, and Y conjugate vaccine) in 10–25-year-olds.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

The Pharma Data

SEPTEMBER 30, 2021

An expert review by a world group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe COVID is so high that booster doses for the overall population aren’t appropriate at this stage within the pandemic.

Vaccine 52

Vaccine Immune Response Disease International 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

BMG Labtech

MARCH 11, 2024

biomarker discovery), blood typing, autoimmune diseases, food science (including allergy testing), infectious disease surveillance, drug discovery and development as well as vaccine development. ELISAs can also be used to measure the antibody responses elicited by vaccines.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6). “We We are excited to be part of the Lyme disease vaccine development program with Valneva.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

MARCH 8, 2022

The Label-CO-VAC is reviewing available data to optimize vaccine intermediated protection against current circulating variants. Still, to insure COVID-19 vaccines give optimal protection into the future, they may need to be streamlined as new, antigenically distinct variants crop.

Vaccine 52

Vaccine Clinical Trials Trials Production 52

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. As described below, it also presents challenges and opportunities for TCR-based therapeutics.

Engineering 110

Engineering DNA Virus Immune Response 110

thought leadership

AUGUST 21, 2023

COVID-19 has presented humankind with the challenges expected from a pandemic with over 700 million cases and almost 7 million deaths 1. Against all odds, the first vaccine available in the USA and the EU for the public was developed following mRNA technology, proving its potential as a new source for vaccine platforms.

Vaccine 40

Vaccine 40

The Pharma Data

MARCH 1, 2022

Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. We believe ASP3772 has significant potential to address unmet needs in this important vaccine category.

Vaccine 52

Vaccine Clinical Trials FDA Therapies 52

keypoint

JULY 25, 2024

The goal of the prize is to accelerate immunology advances with trans-disease applications towards vaccine and immunotherapy innovation. Each will present their groundbreaking work and answer live audience questions about the forefront of vaccine and immunotherapy development during the upcoming live ePanel event.

Science 70

Science Vaccine International Research 70

The Pharma Data

JULY 6, 2021

He and his team reasoned that the virus would likely mutate, potentially in ways that would allow it to escape both natural and vaccine-induced immunity. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccine 52

Vaccine Virus Research Immune Response 52

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 97

RNA Virus DNA Vaccine 97